## UTHR: United Therapeutics Corporation - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_10 at 7.1% exceeds exhaustion threshold (8.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops.

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($487.80)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_10 drops below exhaustion threshold

### News

- **Articles:** 3
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. United Therapeutics (NASDAQ:UTHR) Director Sells $495,950.00 in Stock**
- Source: MarketBeat | 20251216T230922 | Somewhat-Bearish | Relevance: 100%
- United Therapeutics Director Christopher Patusky sold 1,000 shares of the company's stock for $495,950, reducing his stake by over 40%. The company recently reported Q3 EPS of $7.16, beating estimates, but revenue of $799.5 million missed expectations. Analysts currently hold a "Moderate Buy" consensus rating with a $505 target price for United Therapeutics.

**2. Texas Permanent School Fund Corp Increases Holdings in United Therapeutics Corporation $UTHR**
- Source: MarketBeat | 20251215T130907 | Somewhat-Bullish | Relevance: 100%
- Texas Permanent School Fund Corp significantly increased its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 7.2% in the second quarter, valuing its holdings at approximately $14.77 million. This comes despite recent insider selling by executives. Analysts maintain a "Moderate Buy" rating for United Therapeutics with an average price target of $505.00, reflecting confidence in the biotechnology company's performance and future prospects.

**3. Thrivent Financial for Lutherans Has $53.30 Million Holdings in United Therapeutics Corporation $UTHR**
- Source: MarketBeat | 20251215T120907 | Somewhat-Bullish | Relevance: 100%
- Thrivent Financial for Lutherans recently reduced its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 9.8%, now holding 185,477 shares valued at $53.30 million. Insider selling has also been noted, with CEO Martine Rothblatt selling shares, though institutional investors still hold a significant portion of the company. United Therapeutics reported Q3 EPS of $7.16, exceeding estimates, and has a "Moderate Buy" consensus rating with a $505 price target.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 14 ($9.32M) |
| Sells | 75 ($45.40M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Blackrock Inc.: 12.4% (+0.4%)
- Vanguard Group Inc: 10.3% (-0.7%)
- Renaissance Technolo: 5.1% (+2.6%)
- Avoro Capital Adviso: 4.7% (-14.7%)
- State Street Corpora: 4.5% (-11.3%)

### Key Risks

1. Heavy insider selling: $45M sold (75 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_10 improving +6.2% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.44 suggests fair value with growth premium. Forward P/E 17.9x stretched relative to 5% growth. Quality metrics strong (ROA 13%, margin 41%). Balance sheet: strong liquidity (6.4x), low leverage (D/E 0.12). Insider selling cluster ($45.4M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $23.1B |
| Beta | 0.86 |
| 52W Range | $266.98 - $513.93 |
| Short Interest | 5.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.44 |
| Forward P/E | 17.9 |
| Current P/E | 18.9 |
| YoY Growth | 5.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 0.8% to 7.1% (+6.2% in 5 days), confirming momentum buildup. Extended beyond STRENGTH zone (7.1% > 6.0%), caution on chasing. MRS_5 at 4.4% confirms short-term momentum alignment. Outperforming sector by 5.4pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.06), confirming momentum. RSI overbought at 73, risk of mean reversion. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 7.08% (CS: 96) | Strong |
| RSI_14 | 73.1 | Overbought |
| MACD Histogram | 1.06 | Bullish |
| vs SMA20 | 1.053x | Above |
| vs SMA50 | 1.111x | Above |
| vs SMA200 | 1.435x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $510.94
- **Stop Loss:** $487.80 (4.5% risk)
- **Target:** $534.08 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 46
- **Position Value:** $23,503.24
- **Portfolio %:** 23.50%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-25 (Est: $6.88)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $6.96 | $7.16 | +2.9% |
| 2025Q2 | $6.94 | $6.41 | -7.6% |
| 2025Q1 | $6.28 | $6.63 | +5.6% |
| 2024Q4 | $6.27 | $6.19 | -1.2% |

---
*RULE-based L3 | 2026-01-07 01:40 | MRS_10*